

ERS Research Seminar
Lung Cancer Screening: from Trial to Practice
11 – 12 December 2018
Barcelona, Spain

Tuesday, 11 December 2018

08.30 – 08.45 Registration

08.45 – 09.00 Introduction and welcome
Jan van Meerbeeck and Annemie Snoeckx

Session I – Lung cancer screening: what do we know, what don't we know

Chairs: Guido van Hal

09.00 – 09.45 NELSON: the Trafalgar of lung cancer screening?
Harry De Koning (Netherlands)

09.45 – 10.15 General discussion

10.15 – 10.30 *Coffee break*

10.30 – 11.30: Session II – Break out session 1: define per country or per 2 countries

1: How is screening of cancer in general organized in your country?

2: Who are the stakeholders for lung cancer screening implementation in your country?

3: What are the necessary steps for lung cancer screening implementation in your country?

11.30 – 12.15 Plenary report of break out groups

Chairs: Mina Gaga and Torsten Blum

12.15 – 13.00 *Lunch Break*

Session III – Implementation in Europe: hurdles and steps

Chairs: John Field and Annemie Snoeckx

13.00 – 13.20 Participation in screening: lessons learned from the past
Guido Van Hal (Belgium)

13.20 – 13.40 Public understanding and informed decision making: keys to a successful
screening programme
David Ritchie (Belgium)

13.40 – 14.00 How to best target the hard-to-reach? The UK-experience?
Samantha Quaipe (UK)

14.00 – 14.20 The role of patient advocacy groups in implementation
Bert van Herk (Netherlands)

14.20 – 15.00 General discussion

15.00 – 15.30 *Coffee break*

Session IV – Risk assessment strategies

Chairs: Harry De Koning and Torsten Blum

- 15.30 – 15.50 Risk assessment scores: a critical appraisal
Hans-Ulrich Kauczor (Germany)
- 15.50 – 16.10 Breathomics as a possible risk stratification tool to augment lung cancer screening
Marc van der Schee (Netherlands)
- 16.10 – 16.30 Blood biomarkers: ready for practice?
John Field (UK)
- 16.30 – 17.15 Discussion
- 17.15 – 17.30 Summary of the day /introduction to day 2
Jan van Meerbeeck (Belgium)

Wednesday, 12 December 2018

08.30 – 10.00 Session V – Break out session 2: standardisation

*Group 1: Recruitment implementation - Chair: Jan van Meerbeeck
Can we define a minimum common risk assessment strategy for Europe?*

*Group 2: Technical implementation - Chairs Annemie Snoeckx and Hans-Ulrich Kauczor
Can we define a common minimal SOP for nodule handling and follow up?*

10.00 – 10.30 *Coffee break*

10.30 – 11.00 Report from break out groups
Chairs: David Baldwin and Hans-Ulrich Kauczor

Session VI – From trial to practice: concerns of different stakeholders

Chairs: John Field and Hans-Ulrich Kauczor

- 11.00 – 11.20 How will lung cancer screening impact our daily practice? A radiologist's view
Annemie Snoeckx (Belgium)
- 11.20 – 11.40 Artificial Intelligence: an extra clinician we can not ignore
Bram Van Ginneken (Netherlands)
- 11.40 – 12.00 The surgeon's point of view
Herbert Decaluwé (Belgium)
- 12.00 – 12.30 General discussion
- 12.30 – 13.00 *Summing up: remarks, conclusions and action points*
- 13.00 – 14.00 *Lunch and farewell*